Vimarsana
Biggest News Aggregation in the World

Page 15 - Stroke Statistics News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Stroke Statistics. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Stroke Statistics Today - Breaking & Trending Today

American Heart Association: Launches movement to double survival rate from sudden cardiac arrest by 2030 - Vimarsana News

American Heart Association: Launches movement to double survival rate from sudden cardiac arrest by 2030

MADISON, June 1, 2023 — Seven in 10 people in America say they feel powerless to act in the face of a cardiac emergency[1]. As a result, less than half o

Holter Monitoring Systems Market 2023: Business Strategies for Excellent Growth, Highest Revenue, Booming Growth Opportunities – 2030: Nihon Kohden Corporation, VivaQuant, and GE Healthcare | - Vimarsana News

Holter Monitoring Systems Market 2023: Business Strategies for Excellent Growth, Highest Revenue, Booming Growth Opportunities – 2030: Nihon Kohden Corporation, VivaQuant, and GE Healthcare |

Holter Monitoring Systems Market, By End User (Hospitals, Clinics, Diagnostic Centers, Ambulatory Surgical Centers), By Product (Event Monitoring Devices,

Interventions for Heart Failure Should Span Care Continuum - Vimarsana News

Interventions for Heart Failure Should Span Care Continuum

Comprehensive in-hospital planning, postdischarge follow-up, ongoing support are key.

Amarin Highlights New Data Providing Potential Mechanistic Insight into Vascepa®/Vazkepa® (Icosapent Ethyl) Reduction of Cardiovascular Events - Vimarsana News

Amarin Highlights New Data Providing Potential Mechanistic Insight into Vascepa®/Vazkepa® (Icosapent Ethyl) Reduction of Cardiovascular Events

— New Research Demonstrates Multifactorial Beneficial Effects of VASCEPA/VAZKEPA on Coronary Physiology and Plaque Progression — --Data Further Advances Understanding of VASCEPA/VAZKEPA... | May 12, 2023

Farxiga extended in the US to reduce risk of cardiovascular death and hospitalisation for heart failure to a broader range of patients - Vimarsana News

Farxiga extended in the US to reduce risk of cardiovascular death and hospitalisation for heart failure to a broader range of patients

AstraZeneca’s Farxiga (dapagliflozin) has been approved in the US to reduce the risk of cardiovascular (CV) death, hospitalisation for heart failure (hHF) and urgent heart failure (HF) visits in adults with HF. The approval by the Food and Drug Administration (FDA) was based on positive results from the DELIVER ...